APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Inhibitors for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IL-17 Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchIL-17 Inhibitors for Psoriasis Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Inhibitors for Psoriasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal IL-17 Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global IL-17 Inhibitors for Psoriasis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IL-17 Inhibitors for Psoriasis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IL-17 Inhibitors for Psoriasis market include UCB, Kyowa Kirin, LEO Pharma, Ortho Dermatologics, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis and Chongqing Genrix Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-17 Inhibitors for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-17 Inhibitors for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-17 Inhibitors for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-17 Inhibitors for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-17 Inhibitors for Psoriasis Segment by Company

UCB

Kyowa Kirin

LEO Pharma

Ortho Dermatologics

Jiangsu Hengrui Pharmaceuticals

Eli Lilly

Novartis

Chongqing Genrix Biopharmaceutical

IL-17 Inhibitors for Psoriasis Segment by Type

Ixekizumab

Secukinumab

Xeligekimab

Vunakizumab

Brodalumab

Bimelizumab

Other

IL-17 Inhibitors for Psoriasis Segment by Application

Hospital and Clinic

Pharmacy

Other

IL-17 Inhibitors for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global IL-17 Inhibitors for Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IL-17 Inhibitors for Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IL-17 Inhibitors for Psoriasis significant trends, drivers, influence factors in global and regions.

6. To analyze IL-17 Inhibitors for Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Inhibitors for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-17 Inhibitors for Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IL-17 Inhibitors for Psoriasis industry.

Chapter 3: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IL-17 Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IL-17 Inhibitors for Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IL-17 Inhibitors for Psoriasis Industry Trends Table 2. IL-17 Inhibitors for Psoriasis Industry Drivers Table 3. IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges Table 4. IL-17 Inhibitors for Psoriasis Industry Restraints Table 5. Global IL-17 Inhibitors for Psoriasis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IL-17 Inhibitors for Psoriasis Revenue Share by Company (2021-2026) Table 7. Global IL-17 Inhibitors for Psoriasis Sales Volume by Company (Units) & (2021-2026) Table 8. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Company (2021-2026) Table 9. Global IL-17 Inhibitors for Psoriasis Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IL-17 Inhibitors for Psoriasis Company Ranking, (2024-2026) & (USD Million) Table 11. Global IL-17 Inhibitors for Psoriasis Key Company Manufacturing Base & Headquarters Table 12. Global IL-17 Inhibitors for Psoriasis Company, Product Type & Application Table 13. Global IL-17 Inhibitors for Psoriasis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-17 Inhibitors for Psoriasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ixekizumab Table 18. Significant Companies of Secukinumab Table 19. Significant Companies of Xeligekimab Table 20. Significant Companies of Vunakizumab Table 21. Significant Companies of Brodalumab Table 22. Significant Companies of Bimelizumab Table 23. Significant Companies of Other Table 24. Global IL-17 Inhibitors for Psoriasis Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 25. Global IL-17 Inhibitors for Psoriasis Sales Volume by Type (2021-2026) & (Units) Table 26. Global IL-17 Inhibitors for Psoriasis Sales Volume by Type (2027-2032) & (Units) Table 27. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Type (2021-2026) Table 28. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Type (2027-2032) Table 29. Global IL-17 Inhibitors for Psoriasis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global IL-17 Inhibitors for Psoriasis Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global IL-17 Inhibitors for Psoriasis Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Type (2021-2026) Table 33. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Hospital and Clinic Table 35. Significant Companies of Pharmacy Table 36. Significant Companies of Other Table 37. Global IL-17 Inhibitors for Psoriasis Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 38. Global IL-17 Inhibitors for Psoriasis Sales Volume by Application (2021-2026) & (Units) Table 39. Global IL-17 Inhibitors for Psoriasis Sales Volume by Application (2027-2032) & (Units) Table 40. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Application (2021-2026) Table 41. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Application (2027-2032) Table 42. Global IL-17 Inhibitors for Psoriasis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global IL-17 Inhibitors for Psoriasis Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global IL-17 Inhibitors for Psoriasis Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Application (2021-2026) Table 46. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Application (2027-2032) Table 47. Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 48. Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (Units) Table 49. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026) Table 50. Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032) & (Units) Table 51. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2027-2032) Table 52. Global IL-17 Inhibitors for Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global IL-17 Inhibitors for Psoriasis Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Region (2021-2026) Table 55. Global IL-17 Inhibitors for Psoriasis Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Region (2027-2032) Table 57. Global IL-17 Inhibitors for Psoriasis Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global IL-17 Inhibitors for Psoriasis Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 60. Global IL-17 Inhibitors for Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 62. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 63. Global IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 64. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2027-2032) Table 65. Global IL-17 Inhibitors for Psoriasis Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global IL-17 Inhibitors for Psoriasis Sales Value Market Share by Country (2021-2026) Table 67. Global IL-17 Inhibitors for Psoriasis Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global IL-17 Inhibitors for Psoriasis Sales Value Market Share by Country (2027-2032) Table 69. UCB Company Information Table 70. UCB Business Overview Table 71. UCB IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. UCB IL-17 Inhibitors for Psoriasis Product Portfolio Table 73. UCB Recent Development Table 74. Kyowa Kirin Company Information Table 75. Kyowa Kirin Business Overview Table 76. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio Table 78. Kyowa Kirin Recent Development Table 79. LEO Pharma Company Information Table 80. LEO Pharma Business Overview Table 81. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio Table 83. LEO Pharma Recent Development Table 84. Ortho Dermatologics Company Information Table 85. Ortho Dermatologics Business Overview Table 86. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio Table 88. Ortho Dermatologics Recent Development Table 89. Jiangsu Hengrui Pharmaceuticals Company Information Table 90. Jiangsu Hengrui Pharmaceuticals Business Overview Table 91. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio Table 93. Jiangsu Hengrui Pharmaceuticals Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Novartis Company Information Table 100. Novartis Business Overview Table 101. Novartis IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Novartis IL-17 Inhibitors for Psoriasis Product Portfolio Table 103. Novartis Recent Development Table 104. Chongqing Genrix Biopharmaceutical Company Information Table 105. Chongqing Genrix Biopharmaceutical Business Overview Table 106. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio Table 108. Chongqing Genrix Biopharmaceutical Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. IL-17 Inhibitors for Psoriasis Distributors List Table 112. IL-17 Inhibitors for Psoriasis Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. IL-17 Inhibitors for Psoriasis Product Image Figure 2. Global IL-17 Inhibitors for Psoriasis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 4. Global IL-17 Inhibitors for Psoriasis Sales (2021-2032) & (Units) Figure 5. Global IL-17 Inhibitors for Psoriasis Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IL-17 Inhibitors for Psoriasis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ixekizumab Image Figure 10. Secukinumab Image Figure 11. Xeligekimab Image Figure 12. Vunakizumab Image Figure 13. Brodalumab Image Figure 14. Bimelizumab Image Figure 15. Other Image Figure 16. Global IL-17 Inhibitors for Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 17. Global IL-17 Inhibitors for Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Type (2021-2032) Figure 19. Global IL-17 Inhibitors for Psoriasis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global IL-17 Inhibitors for Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Type (2021-2032) Figure 22. Hospital and Clinic Image Figure 23. Pharmacy Image Figure 24. Other Image Figure 25. Global IL-17 Inhibitors for Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 26. Global IL-17 Inhibitors for Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Application (2021-2032) Figure 28. Global IL-17 Inhibitors for Psoriasis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global IL-17 Inhibitors for Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Application (2021-2032) Figure 31. Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global IL-17 Inhibitors for Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global IL-17 Inhibitors for Psoriasis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 36. North America IL-17 Inhibitors for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 38. Europe IL-17 Inhibitors for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 42. South America IL-17 Inhibitors for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. IL-17 Inhibitors for Psoriasis Value Chain Figure 130. Manufacturing Cost Structure Figure 131. IL-17 Inhibitors for Psoriasis Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Secukinumab
  • Xeligekimab
  • Vunakizumab
  • Brodalumab
  • Bimelizumab
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • UCB
  • Kyowa Kirin
  • LEO Pharma
  • Ortho Dermatologics
  • Jiangsu Hengrui Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  4. 1.2.2 Global IL-17 Inhibitors for Psoriasis Sales Volume (2021-2032)
  5. 1.2.3 Global IL-17 Inhibitors for Psoriasis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IL-17 Inhibitors for Psoriasis Market Dynamics
  1. 2.1 IL-17 Inhibitors for Psoriasis Industry Trends
  2. 2.2 IL-17 Inhibitors for Psoriasis Industry Drivers
  3. 2.3 IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges
  4. 2.4 IL-17 Inhibitors for Psoriasis Industry Restraints
3 IL-17 Inhibitors for Psoriasis Market by Company
  1. 3.1 Global IL-17 Inhibitors for Psoriasis Company Revenue Ranking in 2025
  2. 3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026)
  3. 3.3 Global IL-17 Inhibitors for Psoriasis Sales Volume by Company (2021-2026)
  4. 3.4 Global IL-17 Inhibitors for Psoriasis Average Price by Company (2021-2026)
  5. 3.5 Global IL-17 Inhibitors for Psoriasis Company Ranking (2024-2026)
  6. 3.6 Global IL-17 Inhibitors for Psoriasis Company Manufacturing Base and Headquarters
  7. 3.7 Global IL-17 Inhibitors for Psoriasis Company Product Type and Application
  8. 3.8 Global IL-17 Inhibitors for Psoriasis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IL-17 Inhibitors for Psoriasis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IL-17 Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IL-17 Inhibitors for Psoriasis Market by Type
  1. 4.1 IL-17 Inhibitors for Psoriasis Type Introduction
  2. 4.1.1 Ixekizumab
  3. 4.1.2 Secukinumab
  4. 4.1.3 Xeligekimab
  5. 4.1.4 Vunakizumab
  6. 4.1.5 Brodalumab
  7. 4.1.6 Bimelizumab
  8. 4.1.7 Other
  9. 4.2 Global IL-17 Inhibitors for Psoriasis Sales Volume by Type
  10. 4.2.1 Global IL-17 Inhibitors for Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global IL-17 Inhibitors for Psoriasis Sales Volume by Type (2021-2032)
  12. 4.2.3 Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Type (2021-2032)
  13. 4.3 Global IL-17 Inhibitors for Psoriasis Sales Value by Type
  14. 4.3.1 Global IL-17 Inhibitors for Psoriasis Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global IL-17 Inhibitors for Psoriasis Sales Value by Type (2021-2032)
  16. 4.3.3 Global IL-17 Inhibitors for Psoriasis Sales Value Share by Type (2021-2032)
5 IL-17 Inhibitors for Psoriasis Market by Application
  1. 5.1 IL-17 Inhibitors for Psoriasis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Inhibitors for Psoriasis Sales Volume by Application
  6. 5.2.1 Global IL-17 Inhibitors for Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Inhibitors for Psoriasis Sales Volume by Application (2021-2032)
  8. 5.2.3 Global IL-17 Inhibitors for Psoriasis Sales Volume Share by Application (2021-2032)
  9. 5.3 Global IL-17 Inhibitors for Psoriasis Sales Value by Application
  10. 5.3.1 Global IL-17 Inhibitors for Psoriasis Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-17 Inhibitors for Psoriasis Sales Value by Application (2021-2032)
  12. 5.3.3 Global IL-17 Inhibitors for Psoriasis Sales Value Share by Application (2021-2032)
6 IL-17 Inhibitors for Psoriasis Regional Sales and Value Analysis
  1. 6.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021-2026
  4. 6.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032)
  5. 6.3 Global IL-17 Inhibitors for Psoriasis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IL-17 Inhibitors for Psoriasis Sales Value by Region (2021-2032)
  7. 6.4.1 Global IL-17 Inhibitors for Psoriasis Sales Value by Region: 2021-2026
  8. 6.4.2 Global IL-17 Inhibitors for Psoriasis Sales Value by Region (2027-2032)
  9. 6.5 Global IL-17 Inhibitors for Psoriasis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  12. 6.6.2 North America IL-17 Inhibitors for Psoriasis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  15. 6.7.2 Europe IL-17 Inhibitors for Psoriasis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  21. 6.9.2 South America IL-17 Inhibitors for Psoriasis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Value Share by Country, 2025 VS 2032
7 IL-17 Inhibitors for Psoriasis Country-level Sales and Value Analysis
  1. 7.1 Global IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IL-17 Inhibitors for Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IL-17 Inhibitors for Psoriasis Sales by Country (2021-2032)
  4. 7.3.1 Global IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  5. 7.3.2 Global IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032)
  6. 7.4 Global IL-17 Inhibitors for Psoriasis Sales Value by Country (2021-2032)
  7. 7.4.1 Global IL-17 Inhibitors for Psoriasis Sales Value by Country (2021-2026)
  8. 7.4.2 Global IL-17 Inhibitors for Psoriasis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IL-17 Inhibitors for Psoriasis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IL-17 Inhibitors for Psoriasis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IL-17 Inhibitors for Psoriasis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Kyowa Kirin
  8. 8.2.1 Kyowa Kirin Company Information
  9. 8.2.2 Kyowa Kirin Business Overview
  10. 8.2.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio
  12. 8.2.5 Kyowa Kirin Recent Developments
  13. 8.3 LEO Pharma
  14. 8.3.1 LEO Pharma Company Information
  15. 8.3.2 LEO Pharma Business Overview
  16. 8.3.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio
  18. 8.3.5 LEO Pharma Recent Developments
  19. 8.4 Ortho Dermatologics
  20. 8.4.1 Ortho Dermatologics Company Information
  21. 8.4.2 Ortho Dermatologics Business Overview
  22. 8.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio
  24. 8.4.5 Ortho Dermatologics Recent Developments
  25. 8.5 Jiangsu Hengrui Pharmaceuticals
  26. 8.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
  27. 8.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  28. 8.5.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio
  30. 8.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Chongqing Genrix Biopharmaceutical
  44. 8.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 8.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 8.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio
  48. 8.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-17 Inhibitors for Psoriasis Value Chain Analysis
  2. 9.1.1 IL-17 Inhibitors for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-17 Inhibitors for Psoriasis Sales Mode & Process
  6. 9.2 IL-17 Inhibitors for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-17 Inhibitors for Psoriasis Distributors
  9. 9.2.3 IL-17 Inhibitors for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst